MedTrace Logo

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT04722146 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.

Conditions

Interventions

DRUG

Teclistamab

Participants will receive teclistamab.

DRUG

Daratumumab

Participants will receive daratumumab.

DRUG

Pomalidomide

Participants will receive pomalidomide.

DRUG

Lenalidomide

Participants will receive lenalidomide.

DRUG

Bortezomib

Participants will receive bortezomib.

DRUG

Nirogacestat

Participants will receive nirogacestat.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research and Development, LLC Clinical Trial · Janssen Research and Development LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-12
Primary Completion
2027-04-07
Completion
2027-10-13
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04722146 on ClinicalTrials.gov